ERBB3 and head and neck squamous cell carcinoma: In addition, the development of an antibody-drug conjugate (ADC), with a cytotoxic payload attached to an anti-HER3 antibody, may be a promising strategy, owing to the high prevalence of HER3 expression in SCCHN.